KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2023;37(1):10-18 / www.klinickafarmakologie.cz 18 HLAVNÍ TÉMA Čo je nové vo farmakoterapii benígnej hyperplázie prostaty LITERATÚRA 1. Gravas S, Cornu J, Gacci M, et al. EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). [cited 2022 December 15]. Available from: https://uroweb. org/guidelines. 2. Reynolds W, Strand D. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Partin A, Dmochowski R, Kavoussi L, et al., editors. Campbell – Walsh Urology, 12th ed. Saunders Elsevier. 2021:3305-3342. 3. Capogrosso P, Salonia A, Montorsi F. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Partin A, Dmochowski R, Kavoussi L, et al., editors. Campbell – Walsh Urology, 12th ed. Saunders Elsevier. 2021:3343-3402. 4. Marenčák J, Mosnárová A. Súčasné možnosti diagnostiky a liečby benígnej hyperplázie prostaty. Kompendium medicíny 1. 2018:2-15. 5. Lerner L, McVary K, Barry M, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I – initial work-up and medical management. J Urol. 2021;206(4):806-817. 6. Gravas S, Palacios-Moreno J, Thomson D, et al. Understanding treatment response in individual profiles of men with prostatic enlargement at risk of progression. Eur Urol Focus. 2022. In press https://doi.org/10.1016/j.euf.2022.07.004. 7. Yu Z, Yan H, Xu F, et al. Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol. 2020;11:658. doi: 10.3389/fphar.2020.00658. 8. Zámečník L. Non-neurogenní poruchy močení u mužů. In: Zámečník et al., editors. Moderní farmakoterapie v urologii. Maxdorf. 2019:171-185. 9. Gravas S, Bach T, Drake M, et al. Treatment of non-neurogenic male LUTS. In: EAU guidelines on benign prostatic hyperplasia. Arnhem: European Association of Urology. 2017:1-54. 10. Manohar Ch, Nagabhushana M, Karthikeyan V, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH – a double blind randomized trial. Cent European J Urol. 2017;70(1):148-153. 11. Csikós E, Horváth A, Ács K, et al. Treatment of benign prostatic hyperplasia by natural drugs. Molecules. 2021;26(23):7141. doi: 10.3390/molecules26237141. 12. De Nunzio C, Brassetti A, Proietti F, et al. Dutasteride add-on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha-adrenergic antagonist monotherapy: a single center prospective study. Neurourol Urodyn. 2017;36(8):2096-2100. 13. Miernik A, Gratzke Ch. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843-854. 14. Reynolds W, Cohn J. Overactive bladder. In: Partin A, Dmochowski R, Kavoussi L et al., editors. Campbell – Walsh Urology, 12th ed. Saunders Elsevier. 2021:2637-2649. 15. Kreydin E, Gomes C, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091-1107. 16. Lokeshwar S, Harper B, Webb E, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529-539. 17. Marenčák J. Farmakoterapia hyperaktívneho močového mechúra. Klin Urol. 2022;18(3): (v tlači). 18. Horák A. Současná farmakoterapie benigní hyperplazie prostaty dle doporučení EAU. Urol praxi. 2021;22(3):125-132. 19. Herbison P, McKenzie J. Which anticholinergic is best for people with overactive blades? A network meta-analysis. Neurourol Urodyn. 2019;38(2):525-534. 20. Nakagomi H, Mitsui T, Shimura H, et al. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022;22(1):40. doi: 10.1186/s12894022-00989-7. 21. Staskin D, Frankel J, Varano S, et al. International-phase III, randomized, doble blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. J Urol. 2020;204(2):316-324. 22. Marenčák J. Erektilná dysfunkcia a jej liečba. Praktické lekárnictvo. 2017;7(2):53-57. 23. Pattanaik S, Mavuduru R, Panda A, et al. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane database Syst Rev. 2018;11(11):CD010060. 24. Russo G, Scandura C, Di Mauro M, et al. Clinical efficacy of Serrenoa repens versus placebo versus alpha-blockers for the treatment of lower urinary tract symptoms/benign prostatic enlargement: a systematic review amd network meta- -analysis of randomised placebo-contolled clinical trials. Eur Urol Foc. 2021;7(2):420-431. 25. Nagasubramanian S, John N, Antonisami B, et al. Tamsulosin and placebo vs. tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int. 2020;125(5):718-724. 26. De Nunzio C, Salonia A, Gacci M, et al. The role of combination therapy with alpha-blockers and hexanic extract Serenoa repens in the treatment of LUTS/BPH. J Clin Med. 2022;11(23):7169. doi: 10.3390/jcm11237169. 27. Roehrborn C, Oyarzabal I, Roos E, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart®) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int. 2015;116(3):450-459. 28. Kaplan S, Lee J, Meehan A, et al. Time course of incident adverse experiences associated with doxazosin, finasteride and combination therapy in men with benign prostatic hyperplasia: the MTOPS trial. J Urol. 2016;195(6):1825-1829. 29. Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015;31(9):1781-1792. 30. Burgio K, Kraus S, Johnson T, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial. JAMA intern Med. 2020;180(3):411-419. 31. Kaplan S, Herschorn S, McVary K, et al. Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlyingbenign prostatic hyperplasia: a randomized, phase 4 study (PLUS). J Urol. 2020;203(6):1163-1171. 32. Chen P, Wang Ch, Tu Y. Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: a systematic review and meta- -analysis. Uro Sci. 2020;31(3):99-107. 33. Yamanishi T, Asakura H, Seki N, et al. A 52 – week randomized comparative study of a triple therapy (tamsulosin, dutasteride, and imidafenacin) versus a dual therapy (tamsulosin and dutasteride) in benign prostatic hyperplasia patients with overactive bladder (DIrecT Study). Eur Urol Suppl. 2017;16(3):e924. 34. Khizer Z, Sadia A, Sharma R, et al. Drug delivery approaches for managing overactive bladder (OAB): a systematic review. Pharmaceuticals (Basel). 2021;14(5):409. doi: 10.3390/ ph14050409. 35. Peyronnet B, Brucker B, Michel M. Lower urinary tract symptoms: what´s new in medical treatment? Eur Urol Foc. 2018;4(1):17-24. 36. Belos T, Tzelves L, Manolitsis I, et al. Frailty and benign prostatic hyperplasia: the thrilling underlying impact. Arch Ital Urol Androl. 2022;94(3):345-349.
RkJQdWJsaXNoZXIy NDA4Mjc=